Filing identity and reporting period
The supplied filing is Immudyne, Inc.’s Form 10-K for the fiscal year ended December 31, 2013, filed March 28, 2014. It does not identify LifeMD, Inc.; investors should verify that this is the intended issuer. This is an annual report, not a standalone fourth-quarter report.
Business context and financial results
Immudyne manufactures and sells yeast beta-glucan dietary supplements and skincare products. In 2013 it completed its exit from the lower-margin animal-feed additive market and focused on healthcare professionals, distributors, and direct-to-consumer sales.
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Sales | $808,363 | $673,778 | Up 20% |
| Gross profit | $627,059 | $473,870 | Up 32% |
| Gross margin | 77% | 70% | Up 7 percentage points |
| Operating expenses | $1,173,467 | $1,013,895 | Up 16% |
| Operating loss | $(546,408) | $(540,025) | Loss widened slightly |
| Net loss | $(268,262) | $(445,649) | Loss narrowed 40% |
| Net loss per share | $(0.01) | $(0.02) | |
| Cash from operating activities | $(259,074) | $(229,726) | Outflow increased |
Sales growth was attributed mainly to higher raw-material sales to wholesale customers. Gross-margin improvement reflected sales mix and manufacturing economies of scale. Operating costs rose primarily because compensation and related expenses increased to $651,699 from $321,263, including spending on consultants and marketing; general and administrative expense and professional fees declined.
Cash, liquidity, and debt
At December 31, 2013, cash was $155,056; current assets were $450,726 and current liabilities were $325,562, leaving working capital of approximately $125,000 and a current ratio of 1.4 to 1. Total liabilities were $355,962. Current liabilities included $40,200 of demand notes payable to officers, directors, and related individuals, bearing 5% interest, and a $100,000 deposit payable. The filing reports financing cash inflows of $315,200, including equity proceeds, option exercises, increased notes payable, and the deposit.
Management said additional capital would be needed to fund 2014 operating and capital requirements and could be sought through sales growth, equity, or debt. The auditor’s report and management disclosures raise substantial doubt about the company’s ability to continue as a going concern, citing accumulated losses and operating cash outflows; the financial statements contain no adjustments for the outcome of that uncertainty.
Material changes, unusual items, and outlook
- Other income included $210,000 of net legal-settlement proceeds recognized in 2013. A $386,000 settlement was reached in March 2014; the company reported $78,000 net proceeds received during 2013 and a further $132,000 net receivable collected in March 2014. The settlement materially reduced the reported net loss.
- The company received $100,000 from Adiuvo under a memorandum of understanding involving options to acquire company shares and warrants. The contemplated European joint venture was under reconsideration in favor of a possible license; no definitive license was assured. The company reported the $100,000 as a deposit payable at year-end and disclosed that it paid $100,000 to Adiuvo in January 2014 for a minority interest.
- Management planned to increase marketing and expand distribution, including internationally, and expected selling, general, and administrative costs to rise. The filing provides no quantified revenue or earnings guidance.
- Two customers represented 86% of 2013 sales: the largest accounted for 77% (73% in 2012), and the second largest for 9% (12% in 2012). Together they also represented 98% of year-end receivables.
Key risks and contingencies
- Going-concern and financing risk: continuing operating cash outflows and dependence on additional capital or financial support.
- Material weaknesses in internal control over financial reporting and ineffective disclosure controls; management cited inadequate segregation of duties, insufficient accounting and reporting procedures, and weak period-end controls. There was no functioning audit committee or majority of outside directors.
- Product claims and regulatory risk: the company said studies cited were not overseen or endorsed by the FDA or another regulator, and disease-treatment claims are restricted. It also disclosed that it did not maintain product-liability insurance.
- Commercial and execution risk: customer concentration, competition, dependence on key personnel, and uncertainty about the success of its marketing and international expansion plans.
- Related-party exposure: the president held a 60% interest in a skincare royalty arrangement; approximately $50,000 was accrued in accounts payable and the remaining commitment was about $65,000. A director’s law firm received $176,000 in connection with the 2013 settlement, of which $94,000 was paid in 2014.
Important facts for investors to verify
- Confirm the issuer: the filing names Immudyne, Inc., not LifeMD, Inc.
- Assess the company’s ability to fund operations and the terms, timing, and dilution risk of any subsequent financing.
- Verify customer-contract continuity, customer credit quality, and progress in reducing sales and receivables concentration.
- Review the Adiuvo investment, share and warrant options, and whether a definitive European commercial agreement was executed.
- Track remediation of material control weaknesses and confirm settlement proceeds, royalty obligations, and related-party payments.